medigraphic.com
ISSN 1527-3172 (Digital)

2017, Número 2-3

<< Anterior Siguiente >>

MEDICC Review 2017; 19 (2-3)


Association of antineuronal antibody levels with cognitive impairment in older cuban adults

Cristiá-Lara L, Sosa-Pérez S, Urrutia-Amble N, Garrudo-Guirado A, Posada-García A, Galán-García L, Verde-Corvo L, Rodríguez-Morera M, Dorestes-Brown M, Bobes-León MA, Rodríguez-Tanty C, Sablón-Carrazana M, Manrique-Suárez V

Idioma: Ingles.
Referencias bibliográficas: 60
Paginas: 32-39
Archivo PDF: 236.24 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Prince M, Wimo A, Guerchet M, Ali GC, Wu YT. World Alzheimer Report 2015—The Global Impact of Dementia: An analysis of p revalence, incidence, cost and trends. London: Alzheimer’s Disease International; 2015. 83 p.

  2. United Nations Population Division. World Population Ageing, 2015 [Internet]. New York: United Nations; 2015 [cite d 2016 Apr 22]. 4 p. Available from: https://www.un.org/en/development/ desa/population/publications/pdf/ageing/Popula tionAgeingAndDevelopment2015.pdf

  3. Duque-Castaño A, Roldán MI, Arango-Viana JC, Arcos-Burgos M, Cubillo H, Lopera F. [Neuropathological fi ndings in e arly-onset Alzheimer’s disease (E280a-PS1 mutation)]. Rev Neurol. 1999 Jul 1–15;29(1):1–6. Spanish.

  4. Bertram L, Lill CM, Tanzi RE. The genetics of Alzheimer disease: back to the future. Neuron. 2010 Oct 21;68(2):270–8 1.

  5. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDSADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984 Jul;34(7):939–44.

  6. American Psychiatric Association. Diagnostic and statistical manual of mental disorder. 4th ed. Virginia: American P sychiatric Association; 1994 Jan 15. 886 p.

  7. Folstein MF, Folstein SE, McHugh PR. “Minimental state”. A practical method for grading the cognitive state of pati ents for the clinician. J Psychiatr Res. 1975 Nov;12(3):189–98.

  8. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993 Nov;43(11):2412–4.

  9. Beach TG, Monsell SE, Phillips LE, Kukull W. Accuracy of the clinical diagnosis of Alzheimer disease at National Ins titute on Aging Alzheimer Disease Centers, 2005–2010. J Neuropathol Exp Neurol. 2012 Apr;71(4):266–73.

  10. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, et al. Effects of age, sex, and ethnicity on the ass ociation between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA. 1997 Oct 22–29;278(16):1349–56.

  11. National Health Statistics and Medical Records Division (CU). Anuario Estadístico de Salud 2015 [Internet]. Havana: Ministry of Public Health (CU); 2016 Apr 22 [cited 2017 Mar 27]. Available from: http://fi les.sld.cu/dne/ files/2016/04/Anuario_2015_electronico-1 .pdf. Spanish.

  12. National Health Statistics and Medical Records Division (CU). Anuario Estadístico de Salud 2009 [Internet]. Havana: Ministry of Public Health (CU); 2010 [cited 2017 Mar 27]. 243 p. Available from: http://fi les.sld.cu/dne/fi les/2010/04/anuario -2009e3.pdf. Spanish.

  13. Llibre J. Prevenir la enfermedad de Alzheimer. Havana: Editorial Científi co-Técnica; 2009. Spanish.

  14. Llibre JJ, Valhuerdi A, Calvo M, García RM, Guerra M, Laucerique T, et al. Dementia and other chronic diseases in older adults in Havana and Matanzas: the 10/66 study in Cuba. MEDICC Rev. 2011Oct;13(4):30–7.

  15. Llibre JJ, Fernández Y, Marcheco B, Contreras N, López AM, Otero M. Prevalence of Dementia and Alzheimer’s Disease in a H avana Municipality: A Community-Based Study among Elderly Residents. MEDICC Rev. 2009 Apr;11(2):29–35.

  16. Llibre Rodríguez J, Valhuerdi A, Sánchez II, Reyna C, Guerra MA, Copeland JR, et al. The prevalence, correlates and impact of dementia in Cuba. A 10/66 group population-based survey. Neuroepidemiology. 2008;31(4): 243–51.

  17. Llibre-Rodríguez JJ, Valhuerdi-Cepero A, López- Medina AM, Noriega-Fernández L, Porto-Álvarez R, Guerra-Hernández MA, et al. Cuba’s Aging and Alzheimer Longitudinal Study. MEDICC Rev. 2017 Jan;19(1):31–5.

  18. Teruel BM, Rodríguez JJ, McKeigue P, Mesa TC, Fuentes E, Cepero AV, et al. Interactions between genetic admixture, ethnic identity , APOE genotype and dementia prevalence in an admixed Cuban sample; a cross-sectional population survey and nested case–control study. BMC Med Genet. 2011 Mar 24;12:43. DOI: 10.1186/1471- 2350-12-43.

  19. Llibre JJ. Envejecimiento y demencia: implicaciones para la comunidad científi ca, la salud pública y la sociedad cubana. Anales Aca d Ciencias Cuba. 2012;2(2). Spanish.

  20. Prince M, Acosta D, Ferri CP, Guera M, Huang Y, Llibre Rodríguez JJ, et al. Dementia incidence and mortality in middle-incom e countries, and associations with indicators of cognitive reserve: a 10/66 Dementia Research Group population-based cohort study. Lancet. 2012 Jul 7;380(9836):50–8.

  21. Eikelenboom P, van Exel E, Veerhuis R, Rozemuller AJ, van Gool WA, Hoozemans JJ. Innate immunity and the etiology of late-onset Alzheimer’s disease. Neurodegener Dis. 2012;10(1– 4):271–3.

  22. Bouras C, Riederer BM, Kövari E, Hof PR, Giannakopoulos P. Humoral immunity in brain aging and Alzheimer’s disease. Brain Res Brain Re s Rev. 2005 Jun;48(3):477–87.

  23. Levin EC, Acharya NK, Han M, Zavareh SB, Sedeyn JC, Venkataraman V, et al. Brain-reactive autoantibodies are nearly ubiquitous in human sera and may be linked to pathology in the context of blood-brain barrier breakdown. Brain Res. 2010 Jul 23;1345:221–32.

  24. D’Andrea MR. Evidence linking neuronal cell death to autoimmunity in Alzheimer’s disease. Brain Res. 2003 Aug 22;982(1):19–30.

  25. Nagele R G, Clifford PM, Siu G, Levin EC, Acharya NK, Han M, et al. Brain-reactive autoantibodies prevalent in human sera increase intra neuronal amyloid-beta(1–42) deposition. J Alzheimers Dis. 2011;25(4):605–22.

  26. Gruden MA, Davidova TB, Malisauskas M, Sewell RD, Voskresenskaya NI, Wilhem K, et al. Differential neuroimmune markers to the onset of Alzheimer’s disease neurodegeneration and dementia: autoantibodies to Abeta ((25–35)) oligomers, S100b and neurotransmitters. J Neuroimmunol. 2007 May;186(1–2):181–92.

  27. Mor F, Izak M, Cohen IR. Identifi cation of aldolase as a target antigen in Alzheimer’s disease. J Immunol. 2005 Sep 1;175(5):3439–45.

  28. H atzifi lippou E, Koutsouraki E, Banaki T, Traka M, Costa VG, Baloyannis SJ. Antibodies against GM1 in demented patients. Am J Alzheimer s Dis Other Demen. 2008 Jun–Jul;23(3):274–9.

  29. Kankaanpaä J, Turunen SP, Moilanen V, Hörkkö S, Remes AM. Cerebrospinal fl uid antibodies to oxidized LDL are increased in Alzheimer’s d isease. Neurobiol Dis. 2009 Mar;33(3):467–72.

  30. Kellner A, Matschke J, Bernreuther C, Moch H, Ferrer I, Glatzel M. Autoantibodies against betaamyloid are common in Alzheimer’s disease and help control plaque burden. Ann Neurol. 2009 Jan;65(1):24–31.

  31. Brettschneider S, Morgenthaler NG, Teipel SJ, Fischer-Schulz C, Bürger K, Dodel R, et al. Decreased serum amyloid beta (1–42) autoantibody l evels in Alzheimer’s disease, determined by a newly developed immuno-precipitation assay with radiolabeled amyloid beta(1–42) peptide. Biol Psychiatry. 2005 Apr 1;57(7):813–6.

  32. Nath A, Hall E, Tuzova M, Dobbs M, Jons M, Anderson C, et al. Autoantibodies to amyloid beta-peptide (Abeta) are increased in Alzheimer’s dis ease patients and Abeta antibodies can enhance Abeta neurotoxicity: implications for disease pathogenesis and vaccine development. Neuromolecular Med. 2003;3(1):29–39.

  33. Butterfi eld DA, Swomley AM, Sultana R. Amyloid beta-peptide (1–42)-induced oxidative stress in Alzheimer disease: importance in disease pathogenesis and progression. Antioxid Redox Signal. 2013 Sep 10;19(8):823–35.

  34. Walker LC, Jucker M. Neurodegenerative diseases: expanding the prion concept. Annu Rev Neurosci. 2015 Jul 8;38:87–103.

  35. Colasanti T, Barbati C , Rosano G, Malorni W, Ortona E. Autoantibodies in patients with Alzheimer’s disease: pathogenetic role and potential u se as biomarkers of disease progression. Autoimmun Rev. 2010 Oct;9(12):807–11.

  36. Jack CR Jr, Bernstein MA, Borowski BJ, Gunter JL, Fox NC, Thompson PM, et al. Update on the magnetic resonance imaging core of the Alzheimer’ s disease neuroimaging initiative. Alzheimers Dement. 2010 May;6(3):212–20.

  37. Kantarci K. Molecular imaging of Alzheimer disease pathology. Am J Neuroradiol. 2014 Jun;35(6 Suppl):S12–7.

  38. Blennow K, Dubois B, Fagan A M, Lewczuk P, de Leon MJ, Hampel H. Clinical utility of cerebrospinal fl uid biomarkers in the diagnosis of early Alzheimer’s disease. Alzheimers Dement. 2015 Jan;11(1):58–69.

  39. Jack CR Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013 Feb;12(2):207–16.

  40. Wenham PR, Price WH, Blandell G. Apolipoprotein E genotyping by one-stage PCR. Lancet. 1991 May 11;337(8750):1158–9.

  41. Suárez VM, Fernández Y, López Edel C, Clarke DH, Bobes MA, Riverón AM, et al. Apolipoprotein E alleles in Cuban patients with mild cognitive impairment. Am J Alzheimers Dis Other Demen. 2014 May;29(3):236–41.

  42. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256(3):183–94.

  43. Coit P, Ognenovski M, Gensterblum E, Maksimowicz- McKinnon K, Wren JD, Sawalha AH. Ethnicity-specifi c epigenetic variation in naive CD4+ T cells and the susceptibility to autoimmunity. Epigenetics Chromatin. 2015 Nov 24;8:49.

  44. Eric sson C, Peredo I, Nistér M. Optimized protein extraction from cryopreserved brain tissue samples. Acta Oncol. 2007;46(1):10–20.

  45. Dale RC, Candler PM, Church AJ, Wait R, Pocock JM, Giovanni J. Neuronal surface glycolytic enzymes are autoantigen targets in post-streptococcal autoimmune CNS disease. J Neuroimmunol. 2006 Mar;172(1–2):187–97.

  46. Crowt her JR. Methods in Molecular Biology. The ELISA guide book. Vol. 42. New York: Humana Press; 2009. 566 p.

  47. Vadas z Z, Haj T, Kessel A, Toubi E. Age-related autoimmunity. BMC Med. 2013 Apr 4;11:94.

  48. Franc o-Marina F, García-González JJ, Wagner- Echeagaray F, Gallo J, Ugalde O, Sánchez-García S, et al. The Mini-mental State Examination revisited: ceiling and fl oor effects after score adjustment for educational level in an aging Mexican population. Int Psychogeriatr. 2010 Feb;22(1):72–81.

  49. Hanley JA , McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology. 1983 Sep;148(3):839–43.

  50. Cerda J, Cifuentes L. [Using ROC curves in clinical investigation: theoretical and practical issues]. Rev Chilena Infectol. 2012 Apr;29(2):138– 41. Spanish.

  51. Douglas J N, Gardner LA, Levin MC. Antibodies to an intracellular antigen penetrate neuronal cells and cause deleterious effects. J Clin Cell Immunol. 2013 Jan 30;4(1).

  52. Dodel R, Balakrishnan K, Keyvani K, Deuster O, Neff F, Andrei-Selmer LC, et al. Naturally occurring autoantibodies against beta-amyloid: investigating their role in transgenic animal and in vitro models of Alzheimer’s disease. J Neurosci. 2011 Apr 13;31(15):5847–54.

  53. Gustaw-Ro thenberg KA, Siedlak SL, Bonda DJ, Lerner A, Tabaton M, Perry G, et al. Dissociated amyloid-beta antibody levels as a serum biomarker for the progression of Alzheimer’s disease: a population-based study. Exp Gerontol. 2010 Jan; 45(1):47–52.

  54. Storace D , Cammarata S, Borghi R, Sanguineti R, Giliberto L, Piccini A, et al. Elevation of {beta}- amyloid 1–42 autoantibodies in the blood of amnestic patients with mild cognitive impairment. Arch Neurol. 2010 Jul;67(7):867–72.

  55. Klaver AC , Coffey MP, Smith LM, Bennett DA, Finke JM, Dang L, et al. ELISA measurement of specifi c non-antigen-bound antibodies to Abeta1-42 monomer and soluble oligomers in sera from Alzheimer’s disease, mild cognitively impaired, and noncognitively impaired subjects. J Neuroinfl ammation. 2011 Aug 9;8:93.

  56. Maftei M, Thurm F, Schnack C, Tumani H, Otto M, Elbert T, et al. Increased levels of antigenbound beta-amyloid autoantibodies in serum and cerebrospinal fl uid of Alzheimer’s disease patients. PLoS One. 2013 Jul 18;8(7):e68996.

  57. Mruthinti S, Buccafusco JJ, Hill WD, Waller JL, Jackson TW, Zamrini EY, et al. Autoimmunity in Alzheimer’s disease: increased levels of circulating IgGs binding Abeta and RAGE peptides. Neurobiol Aging. 2004 Sep;25(8):1023–32.

  58. Tuohy VK, Kinkel RP. Epitope spreading: a mechanism for progression of autoimmune disease. Arch Immunol Ther Exp (Warsz). 2000;48(5):347–51.

  59. Weisman D , Hakimian E, Ho GJ. Interleukins, infl ammation, and mechanisms of Alzheimer’s disease. Vitam Horm. 2006;74:505–30.

  60. Leon AC, Davis LL, Kraemer HC. The role and interpretation of pilot studies in clinical research. J Psychiatr Res. 2011 May;45(5):626–9.




2020     |     www.medigraphic.com